Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders
Yam Nath Paudel(Monash University Malaysia), Mohd. Farooq Shaikh(University of Mumbai), Christina Piperi(National and Kapodistrian University of Athens), Efthalia Angelopoulou(National and Kapodistrian University of Athens), Iekhsan Othman(Monash University Malaysia), Bridgette D. Semple(The Royal Melbourne Hospital)
Cited by 105
Related Papers
HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction
|Frontiers in Neuroscience|2018|318
Current strategies in extending half-lives of therapeutic proteins
|Journal of Controlled Release|2019|285
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
|Cells|2020|257
Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity
|Frontiers in Microbiology|2015|178
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling
|European Journal of Pharmacology|2019|175